The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants acalabrutinib Priority Review for the possible treatment of relapsed/refractory Mantle Cell Lymphoma
On 2nd August 2017, a New Drug Application (NDA) for acalabrutinib was granted Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).
This announcement follows acalabrutinib being awarded Breakthrough Therapy Designation (BTD) only one day previously; read more here. Similar to the BTD submission, the NDA is supported partly by results from the phase II ACE-LY-004 trial (NCT02213926).
It is expected that the FDA will make a final approval decision for acalabrutinib in the setting of R/R MCL in early 2018.
References